Europe Parkinson's Disease Treatment Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Parkinson's Disease Treatment Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Levodopa/carbidopa Market Performance (Volume)
  • 2.1.2 Dopamine Receptor Agonists Market Performance (Volume)
  • 2.1.3 MAO-Inhibitors Market Performance (Volume)
  • 2.1.4 COMT-inhibitors Market Performance (Volume)
  • 2.1.5 Anticholinergics Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Levodopa/carbidopa Market Performance (Value)
  • 2.1.2 Dopamine Receptor Agonists Market Performance (Value)
  • 2.1.3 MAO-Inhibitors Market Performance (Value)
  • 2.1.4 COMT-inhibitors Market Performance (Value)
  • 2.1.5 Anticholinergics Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Hospital Pharmacies Market Performance (Volume)
  • 3.1.2 Retailer Pharmacies Market Performance (Volume)
  • 3.1.3 Online Pharmacies Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Teva (Israel)
  • 4.1.1 Teva (Israel) Profiles
  • 4.1.2 Teva (Israel) Product Information
  • 4.1.3 Teva (Israel) Parkinson's Disease Treatment Business Performance
  • 4.1.4 Teva (Israel) Parkinson's Disease Treatment Business Development and Market Status
• 4.2 Novartis AG (Switzerland)
  • 4.2.1 Novartis AG (Switzerland) Profiles
  • 4.2.2 Novartis AG (Switzerland) Product Information
  • 4.2.3 Novartis AG (Switzerland) Parkinson's Disease Treatment Business Performance
  • 4.2.4 Novartis AG (Switzerland) Parkinson's Disease Treatment Business Development and Market Status
• 4.3 GSK (UK)
  • 4.3.1 GSK (UK) Profiles
  • 4.3.2 GSK (UK) Product Information
  • 4.3.3 GSK (UK) Parkinson's Disease Treatment Business Performance
  • 4.3.4 GSK (UK) Parkinson's Disease Treatment Business Development and Market Status
• 4.4 AbbVie (US)
  • 4.4.1 AbbVie (US) Profiles
  • 4.4.2 AbbVie (US) Product Information
  • 4.4.3 AbbVie (US) Parkinson's Disease Treatment Business Performance
  • 4.4.4 AbbVie (US) Parkinson's Disease Treatment Business Development and Market Status
• 4.5 Merck (US)
  • 4.5.1 Merck (US) Profiles
  • 4.5.2 Merck (US) Product Information
  • 4.5.3 Merck (US) Parkinson's Disease Treatment Business Performance
  • 4.5.4 Merck (US) Parkinson's Disease Treatment Business Development and Market Status
• 4.6 Boehringer Ingelheim (Germany)
  • 4.6.1 Boehringer Ingelheim (Germany) Profiles
  • 4.6.2 Boehringer Ingelheim (Germany) Product Information
  • 4.6.3 Boehringer Ingelheim (Germany) Parkinson's Disease Treatment Business Performance
  • 4.6.4 Boehringer Ingelheim (Germany) Parkinson's Disease Treatment Business Development and Market Status
• 4.7 Impax Laboratories (US)
  • 4.7.1 Impax Laboratories (US) Profiles
  • 4.7.2 Impax Laboratories (US) Product Information
  • 4.7.3 Impax Laboratories (US) Parkinson's Disease Treatment Business Performance
  • 4.7.4 Impax Laboratories (US) Parkinson's Disease Treatment Business Development and Market Status
• 4.8 Lundbeck (Denmark)
  • 4.8.1 Lundbeck (Denmark) Profiles
  • 4.8.2 Lundbeck (Denmark) Product Information
  • 4.8.3 Lundbeck (Denmark) Parkinson's Disease Treatment Business Performance
  • 4.8.4 Lundbeck (Denmark) Parkinson's Disease Treatment Business Development and Market Status
• 4.9 UCB (Belgium)
  • 4.9.1 UCB (Belgium) Profiles
  • 4.9.2 UCB (Belgium) Product Information
  • 4.9.3 UCB (Belgium) Parkinson's Disease Treatment Business Performance
  • 4.9.4 UCB (Belgium) Parkinson's Disease Treatment Business Development and Market Status
• 4.10 Valeant Pharmaceuticals (Canada)
  • 4.10.1 Valeant Pharmaceuticals (Canada) Profiles
  • 4.10.2 Valeant Pharmaceuticals (Canada) Product Information
  • 4.10.3 Valeant Pharmaceuticals (Canada) Parkinson's Disease Treatment Business Performance
  • 4.10.4 Valeant Pharmaceuticals (Canada) Parkinson's Disease Treatment Business Development and Market Status
• 4.11 Acadia (US)
• 4.12 Sun Pharma (India)
• 4.13 GSK (UK)
• 4.14 AbbVie (US)
• 4.15 Merck (US)

5 Market Performance for Manufacturers

• 5.1 Europe Parkinson's Disease Treatment Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Parkinson's Disease Treatment Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Parkinson's Disease Treatment Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Parkinson's Disease Treatment Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Parkinson's Disease Treatment Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Parkinson's Disease Treatment Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Parkinson's Disease Treatment Market Performance (Sales Point)

• 7.1 Europe Parkinson's Disease Treatment Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Parkinson's Disease Treatment Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Parkinson's Disease Treatment Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Parkinson's Disease Treatment Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Parkinson's Disease Treatment Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Hospital Pharmacies Industry
• 11.2 Retailer Pharmacies Industry
• 11.3 Online Pharmacies Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Parkinson's Disease Treatment Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Parkinson's Disease Treatment Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Levodopa/carbidopa Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Dopamine Receptor Agonists Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 MAO-Inhibitors Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 COMT-inhibitors Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Hospital Pharmacies Sales and and Growth Rate 2019-2024
  • 12.4.3 Retailer Pharmacies Sales and and Growth Rate 2019-2024
  • 12.4.4 Online Pharmacies Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Parkinson's Disease Treatment Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Parkinson's Disease Treatment Gross Profit Trend 2019-2024

13 Conclusion